A Decade in Focus: Examining Lessons Learned From Office-Directed Injectables in an Academic Practice
Authors:
- Vidhya NadarajanVNVidhya Nadarajan
- Bhavana ThotaBTBhavana Thota
- Anca DogaroiuADAnca Dogaroiu
- Lauren KimLKLauren Kim
- Amor NiksicANAmor Niksic
- Victoria PetersVPVictoria Peters
- Tuong-Vi Cindy NgoTNTuong-Vi Cindy Ngo
- Jennifer BarillasJBJennifer Barillas
- Jeffrey KenkelJKJeffrey Kenkel
Open Access
- 8 January 2025
- journal article
- Published by Oxford University Press (OUP) in Aesthetic Surgery Journal Open Forum
- Vol. 7, ojaf013
Abstract
Background: Noninvasive facial rejuvenation procedures have continued to grow in popularity, with botulinum toxin and injectable soft-tissue fillers being the most common. Objectives: The purpose of this study was to evaluate trends in patient cost, provider product preferences, and complications of a single surgeon's 10-year experience with botulinum toxin and soft-tissue fillers. Additionally, this study aimed to quantify the crossover between patients receiving injectables and patients receiving aesthetic surgery. Methods: This was a retrospective analysis utilizing internal/departmental records and Epic charting from January 2013 to January 2023. Botulinum toxin and soft-tissue filler cases were captured using select CPT codes, and patient demographics, complications, and follow-up data were recorded. Results: One thousand three hundred and sixty-eight patients undergoing 5794 injectable cases were assessed. The study population was majority female (89.3%) and Caucasian (78.7%). Injectable cases increased over time, except for a decrease in 2020. Botulinum toxin was most common (59%), followed by fillers (18%), and combination therapy (19%). Common injection sites included the glabella, crow's feet, and forehead for neurotoxins and marionette lines and nasolabial folds for fillers. Complications were rare, with 35 from botulinum toxin and 33 from fillers. Of patients receiving injectables, 19.6% went on to receive an aesthetic surgery, and 0.6% of patients undergoing aesthetic surgery subsequently received injectables. Conclusions: Botulinum toxin and soft-tissue fillers are safe with low complication rates when administered by an experienced provider. These procedures may serve as a starting point for patients pursuing antiaging treatments and an opportunity to establish continuity of care for providers. Level of Evidence: 4 (Therapeutic):Keywords
This publication has 40 references indexed in Scilit:
- Complications of minimally invasive cosmetic procedures: Prevention and managementJournal of Cutaneous and Aesthetic Surgery, 2012
- Etiology, Prevention, and Treatment of Dermal Filler ComplicationsAesthetic Surgery Journal, 2011
- Complications in Periocular RejuvenationFacial Plastic Surgery Clinics of North America, 2010
- Evaluation of Variable-Dose Treatment with a New U.S. Botulinum Toxin Type A (Dysport) for Correction of Moderate to Severe Glabellar Lines: Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled StudyPlastic and Reconstructive Surgery, 2009
- An Overview of Clinical Trial Data on a New Formulation of Botulinum Neurotoxin Type AAesthetic Surgery Journal, 2009
- Risks and Opportunities for Plastic Surgeons in a Widening Cosmetic Medicine Market: Future Demand, Consumer Preferences, and Trends in Practitioners’ ServicesPlastic and Reconstructive Surgery, 2008
- Injectable Treatments for the Aging FaceFacial Plastic Surgery, 2006
- Botulinum toxin type A injections: Adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic casesJournal of the American Academy of Dermatology, 2005
- A Randomized, Double-Blind, Multicenter Comparison of the Efficacy and Tolerability of Restylane Versus Zyplast for the Correction of Nasolabial FoldsDermatologic Surgery, 2003
- Complications and adverse reactions with the use of botulinum toxinDisease-a-Month, 2002